ALT
Price
$6.99
Change
+$0.04 (+0.58%)
Updated
Jan 30, 04:59 PM (EDT)
Capitalization
494.32M
55 days until earnings call
CLDX
Price
$25.68
Change
+$0.42 (+1.66%)
Updated
Jan 31, 10:38 AM (EDT)
Capitalization
1.69B
31 days until earnings call
Ad is loading...

ALT vs CLDX

Header iconALT vs CLDX Comparison
Open Charts ALT vs CLDXBanner chart's image
Altimmune
Price$6.99
Change+$0.04 (+0.58%)
Volume$23.42K
Capitalization494.32M
Celldex Therapeutics
Price$25.68
Change+$0.42 (+1.66%)
Volume$200
Capitalization1.69B
ALT vs CLDX Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. CLDX commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and CLDX is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (ALT: $7.00 vs. CLDX: $25.26)
Brand notoriety: ALT and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 57% vs. CLDX: 63%
Market capitalization -- ALT: $494.32M vs. CLDX: $1.69B
ALT [@Biotechnology] is valued at $494.32M. CLDX’s [@Biotechnology] market capitalization is $1.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, CLDX is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 6 TA indicator(s) are bullish while CLDX’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 6 bullish, 2 bearish.
  • CLDX’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, ALT is a better buy in the short-term than CLDX.

Price Growth

ALT (@Biotechnology) experienced а -0.85% price change this week, while CLDX (@Biotechnology) price change was +3.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.11%. For the same industry, the average monthly price growth was +1.05%, and the average quarterly price growth was +4.49%.

Reported Earning Dates

ALT is expected to report earnings on May 20, 2025.

CLDX is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.69B) has a higher market cap than ALT($494M). CLDX YTD gains are higher at: -0.040 vs. ALT (-2.913). ALT has higher annual earnings (EBITDA): -103.19M vs. CLDX (-171.06M). CLDX has more cash in the bank: 756M vs. ALT (139M). ALT has less debt than CLDX: ALT (1.77M) vs CLDX (3.09M). CLDX has higher revenues than ALT: CLDX (9.98M) vs ALT (52K).
ALTCLDXALT / CLDX
Capitalization494M1.69B29%
EBITDA-103.19M-171.06M60%
Gain YTD-2.913-0.0407,360%
P/E RatioN/AN/A-
Revenue52K9.98M1%
Total Cash139M756M18%
Total Debt1.77M3.09M57%
FUNDAMENTALS RATINGS
ALT vs CLDX: Fundamental Ratings
ALT
CLDX
OUTLOOK RATING
1..100
88
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
7948
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
5862
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (57) in the Biotechnology industry is somewhat better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew somewhat faster than ALT’s over the last 12 months.

CLDX's Profit vs Risk Rating (48) in the Biotechnology industry is in the same range as ALT (79) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew similarly to ALT’s over the last 12 months.

CLDX's SMR Rating (96) in the Biotechnology industry is in the same range as ALT (98) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew similarly to ALT’s over the last 12 months.

ALT's Price Growth Rating (58) in the Miscellaneous Commercial Services industry is in the same range as CLDX (62) in the Biotechnology industry. This means that ALT’s stock grew similarly to CLDX’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as CLDX (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTCLDX
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 24 days ago
85%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 30 days ago
88%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
77%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEGIX29.690.90
+3.13%
First Eagle Gold I
JVMRX27.93N/A
N/A
JHancock Disciplined Value Mid Cap R6
GAGCX31.13N/A
N/A
Gabelli Global Rising Income and Div AAA
SFENX9.25N/A
N/A
Schwab Fundamental Emerging Mkts Eq Idx
FCGBX2.47N/A
N/A
Templeton Global Balanced C

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with CLDX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
+0.72%
CLDX - ALT
47%
Loosely correlated
-0.98%
KRYS - ALT
46%
Loosely correlated
-0.15%
DNLI - ALT
44%
Loosely correlated
+0.73%
VERV - ALT
42%
Loosely correlated
-3.77%
PLRX - ALT
41%
Loosely correlated
-0.74%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KRYS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-0.98%
KRYS - CLDX
57%
Loosely correlated
-0.15%
ALT - CLDX
46%
Loosely correlated
+0.72%
AXON - CLDX
43%
Loosely correlated
+2.10%
BEAM - CLDX
42%
Loosely correlated
+5.29%
KYMR - CLDX
42%
Loosely correlated
+2.66%
More